Condition: Coronary Artery Disease · Sponsor: Seoul National University Hospital
The investigators will evaluate the efficacy and safety of clopidogrel for primary prevention in patients diagnosed with coronary atherosclerosis on imaging that did not require revascularization therapy. The trial will test the hypothesis that clopidogrel is beneficial in preventing major adverse cardiovascular and cerebrovascular events (MACCE) in patients with subclinical coronary atherosclerosis identified on imaging.
This description comes directly from the study's public registry record.
Jung-Kyu Han, MD, PhD · 821026765736 · hpcrates@gmail.com
Always discuss trial participation with your own doctor first.
| Seoul National University Hospital | Seoul, Other, South Korea | Recruiting |
| Andong Hospital | Andong, South Korea | Recruiting |
| Dong-A University Hospital | Busan, South Korea | Recruiting |
| Inje University Busan Paik Hospital | Busan, South Korea | Recruiting |
| Kosin University Gospel Hospital | Busan, South Korea | Recruiting |
| Pusan National University Hospital | Busan, South Korea | Recruiting |
| Gyeongsang National University Changwon Hospital | Changwon, South Korea | Recruiting |
| Soonchunhyang University Cheonan Hospital | Cheonan, South Korea | Recruiting |
| Soonchunhyang University Cheonan Hospital | Cheonan, South Korea | Recruiting |
| Soonchunhyang University Cheonan Hospital | Cheonan, South Korea | Recruiting |
| Chungbuk National University Hospital | Cheongju-si, South Korea | Recruiting |
| Hallym University Chuncheon Sacred Heart Hospital | Chuncheon, South Korea | Recruiting |
+ 49 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05845489